Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.

Kaushik A, Ammerman NC, Parrish NM, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00733-19. doi: 10.1128/AAC.00733-19. Print 2019 Sep.

PMID:
31209013
2.

Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.

Converse PJ, Almeida DV, Tyagi S, Xu J, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00426-19. doi: 10.1128/AAC.00426-19. Print 2019 Jul.

PMID:
31036687
3.

Advancing the Therapeutic Potential of Indoleamides for Tuberculosis.

Lun S, Tasneen R, Chaira T, Stec J, Onajole OK, Yang TJ, Cooper CB, Mdluli K, Converse PJ, Nuermberger EL, Raj VS, Kozikowski A, Bishai WR.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00343-19. doi: 10.1128/AAC.00343-19. Print 2019 Jul.

4.

Understanding the Significance of Biochemistry in the Storage, Handling, Purification, and Sampling of Amphiphilic Mycolactone.

Kubicek-Sutherland JZ, Vu DM, Anderson AS, Sanchez TC, Converse PJ, Martí-Arbona R, Nuermberger EL, Swanson BI, Mukundan H.

Toxins (Basel). 2019 Apr 4;11(4). pii: E202. doi: 10.3390/toxins11040202.

5.

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus.

Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. doi: 10.1128/AAC.00470-19. Print 2019 Jun.

PMID:
30962331
6.

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.

Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00021-19. doi: 10.1128/AAC.00021-19. Print 2019 May.

7.

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro.

Pandey R, Chen L, Manca C, Jenkins S, Glaser L, Vinnard C, Stone G, Lee J, Mathema B, Nuermberger EL, Bonomo RA, Kreiswirth BN.

MBio. 2019 Feb 12;10(1). pii: e02895-18. doi: 10.1128/mBio.02895-18.

8.

In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.

Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02623-18. doi: 10.1128/AAC.02623-18. Print 2019 Mar.

9.

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.

Almeida DV, Omansen TF, Li SY, Lee J, Grosset JH, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02171-18. doi: 10.1128/AAC.02171-18. Print 2019 Mar.

10.

High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.

Omansen TF, Almeida D, Converse PJ, Li SY, Lee J, Stienstra Y, van der Werf T, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01478-18. doi: 10.1128/AAC.01478-18. Print 2019 Feb.

11.

Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research.

Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM.

Am J Respir Crit Care Med. 2019 Apr 15;199(8):947-951. doi: 10.1164/rccm.201807-1273PP. No abstract available.

PMID:
30428263
12.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

Converse PJ, Almeida DV, Tasneen R, Saini V, Tyagi S, Ammerman NC, Li SY, Anders NM, Rudek MA, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.

13.

Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.

Park SW, Tasneen R, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01502-17. doi: 10.1128/AAC.01502-17. Print 2017 Nov.

14.

Preclinical Efficacy Testing of New Drug Candidates.

Nuermberger EL.

Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0034-2017. Review.

PMID:
28643624
15.

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.

Li SY, Tasneen R, Tyagi S, Soni H, Converse PJ, Mdluli K, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00913-17. doi: 10.1128/AAC.00913-17. Print 2017 Sep.

16.

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G.

J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152.

17.

New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.

Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM.

Clin Transl Sci. 2017 Sep;10(5):366-379. doi: 10.1111/cts.12472. Epub 2017 May 31.

18.

Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9.

Ordonez AA, Tasneen R, Pokkali S, Xu Z, Converse PJ, Klunk MH, Mollura DJ, Nuermberger EL, Jain SK.

Dis Model Mech. 2016 Jul 1;9(7):779-88. doi: 10.1242/dmm.025643. Epub 2016 May 26.

19.

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice.

Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, Chen C, Reichlen MJ, Asay BC, Voskuil MI, Nuermberger EL, Andries K, Lyons MA, Dartois V, Lenaerts AJ.

ACS Infect Dis. 2016 Apr 8;2(4):251-267. Epub 2016 Feb 24.

20.

Extensively drug-resistant tuberculosis in a young child after travel to India.

Salazar-Austin N, Ordonez AA, Hsu AJ, Benson JE, Mahesh M, Menachery E, Razeq JH, Salfinger M, Starke JR, Milstone AM, Parrish N, Nuermberger EL, Jain SK.

Lancet Infect Dis. 2015 Dec;15(12):1485-91. doi: 10.1016/S1473-3099(15)00356-4. Epub 2015 Nov 16. Review.

21.

Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?

Lanoix JP, Chaisson RE, Nuermberger EL.

Clin Infect Dis. 2016 Feb 15;62(4):484-90. doi: 10.1093/cid/civ911. Epub 2015 Nov 1.

22.

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):270-7. doi: 10.1128/AAC.01691-15. Print 2016 Jan.

23.

Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.

Converse PJ, Tyagi S, Xing Y, Li SY, Kishi Y, Adamson J, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2015 Jun 4;9(6):e0003823. doi: 10.1371/journal.pntd.0003823. eCollection 2015.

24.

Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.

Lanoix JP, Lenaerts AJ, Nuermberger EL.

Dis Model Mech. 2015 Jun;8(6):603-10. doi: 10.1242/dmm.019513. Epub 2015 Mar 30.

25.

Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis.

Irwin SM, Driver E, Lyon E, Schrupp C, Ryan G, Gonzalez-Juarrero M, Basaraba RJ, Nuermberger EL, Lenaerts AJ.

Dis Model Mech. 2015 Jun;8(6):591-602. doi: 10.1242/dmm.019570. Epub 2015 Mar 30.

26.

Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.

Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Jul;59(7):4026-30. doi: 10.1128/AAC.00105-15. Epub 2015 Apr 27.

27.

A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.

Locher CP, Jones SM, Hanzelka BL, Perola E, Shoen CM, Cynamon MH, Ngwane AH, Wiid IJ, van Helden PD, Betoudji F, Nuermberger EL, Thomson JA.

Antimicrob Agents Chemother. 2015 Mar;59(3):1455-65. doi: 10.1128/AAC.04347-14. Epub 2014 Dec 22.

28.

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Erratum in: Am J Respir Crit Care Med. 2015 May 15;191(10):1210.

29.

Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.

Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Jan;59(1):129-35. doi: 10.1128/AAC.03822-14. Epub 2014 Oct 20.

30.

Minding the gaps in tuberculosis research.

Ekins S, Nuermberger EL, Freundlich JS.

Drug Discov Today. 2014 Sep;19(9):1279-82. doi: 10.1016/j.drudis.2014.06.022. Epub 2014 Jun 30. No abstract available.

PMID:
24993157
31.

Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.

Irwin SM, Gruppo V, Brooks E, Gilliland J, Scherman M, Reichlen MJ, Leistikow R, Kramnik I, Nuermberger EL, Voskuil MI, Lenaerts AJ.

Antimicrob Agents Chemother. 2014 Jul;58(7):4026-34. doi: 10.1128/AAC.02565-14. Epub 2014 May 5.

32.

Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease.

Converse PJ, Xing Y, Kim KH, Tyagi S, Li SY, Almeida DV, Nuermberger EL, Grosset JH, Kishi Y.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2618. doi: 10.1371/journal.pntd.0002618. eCollection 2014.

33.

Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.

Zhang T, Li SY, Converse PJ, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2598. doi: 10.1371/journal.pntd.0002598. eCollection 2013.

34.

Pipeline of drugs for related diseases: tuberculosis.

Dooley KE, Nuermberger EL, Diacon AH.

Curr Opin HIV AIDS. 2013 Nov;8(6):579-85. doi: 10.1097/COH.0000000000000009. Review.

35.

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.

Dutta NK, Alsultan A, Gniadek TJ, Belchis DA, Pinn ML, Mdluli KE, Nuermberger EL, Peloquin CA, Karakousis PC.

Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13. Epub 2013 Jun 3.

36.

Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2013 Jul 1;188(1):97-102. doi: 10.1164/rccm.201212-2328OC.

37.

Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.

Almeida DV, Converse PJ, Li SY, Tyagi S, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2013;7(2):e2085. doi: 10.1371/journal.pntd.0002085. Epub 2013 Feb 28.

38.

Reply to "Contradictory results with high-dosage rifamycin in mice and humans".

Nuermberger EL, Rosenthal IM, Tasneen R, Peloquin CA, Mdluli KE, Karakousis PC, Grosset JH.

Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. No abstract available.

39.

Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.

Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, Peck KM, Welch JT, Baughn AS, Jacobs WR Jr, Grosset JH.

Indian J Med Res. 2012 Nov;136(5):808-14.

40.

Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials.

Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11. doi: 10.1073/pnas.1214188109. Epub 2012 Sep 10.

41.

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium.

J Infect Dis. 2012 Oct 1;206(7):1030-40. Epub 2012 Jul 30.

PMID:
22850121
42.

World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL; Efficacy Subgroup, RESIST-TB.

J Infect Dis. 2013 May 1;207(9):1352-8. doi: 10.1093/infdis/jis460. Epub 2012 Jul 17. Review.

43.

Confronting multidrug-resistant tuberculosis.

Chaisson RE, Nuermberger EL.

N Engl J Med. 2012 Jun 7;366(23):2223-4. doi: 10.1056/NEJMe1204478. No abstract available.

PMID:
22670908
44.

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4.

45.

2011: the year in review. part I: tuberculosis.

Chang KC, Nuermberger EL.

Int J Tuberc Lung Dis. 2012 Jun;16(6):740-8. doi: 10.5588/ijtld.12.0139. Review.

PMID:
22613685
46.

Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.

Dutta NK, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset JH, Karakousis PC.

Antimicrob Agents Chemother. 2012 Jul;56(7):3726-31. doi: 10.1128/AAC.00500-12. Epub 2012 Apr 30.

47.

Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.

Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE.

Clin Pharmacol Ther. 2012 May;91(5):881-8. doi: 10.1038/clpt.2011.323.

48.

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. doi: 10.1128/AAC.00384-12. Epub 2012 Apr 2.

49.

Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy.

Zhang T, Li SY, Nuermberger EL.

PLoS One. 2012;7(1):e29774. doi: 10.1371/journal.pone.0029774. Epub 2012 Jan 11.

50.

Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.

Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK.

J Infect Dis. 2012 Feb 15;205(4):595-602. doi: 10.1093/infdis/jir786. Epub 2011 Dec 23.

Supplemental Content

Loading ...
Support Center